BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23214999)

  • 1. Theoretical investigations and density functional theory based quantitative structure-activity relationships model for novel cytotoxic platinum(IV) complexes.
    Varbanov HP; Jakupec MA; Roller A; Jensen F; Galanski MS; Keppler BK
    J Med Chem; 2013 Jan; 56(1):330-44. PubMed ID: 23214999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bis- and Tetrakis(carboxylato)platinum(IV) complexes with mixed axial ligands - synthesis, characterization, and cytotoxicity.
    Hoffmeister BR; Hejl M; Adib-Razavi MS; Jakupec MA; Galanski M; Keppler BK
    Chem Biodivers; 2015 Apr; 12(4):559-74. PubMed ID: 25879501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel class of bis- and tris-chelate diam(m)inebis(dicarboxylato)platinum(IV) complexes as potential anticancer prodrugs.
    Varbanov HP; Göschl S; Heffeter P; Theiner S; Roller A; Jensen F; Jakupec MA; Berger W; Galanski MS; Keppler BK
    J Med Chem; 2014 Aug; 57(15):6751-64. PubMed ID: 25032896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platinum(II) complexes of imidazophenanthroline-based polypyridine ligands as potential anticancer agents: synthesis, characterization, in vitro cytotoxicity studies and a comparative ab initio, and DFT studies with cisplatin, carboplatin, and oxaliplatin.
    Alexander C; Nithyakumar A; Paul MWB; Arockia Samy N
    J Biol Inorg Chem; 2018 Jul; 23(5):833-848. PubMed ID: 29934700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel tetracarboxylatoplatinum(IV) complexes as carboplatin prodrugs.
    Varbanov HP; Valiahdi SM; Kowol CR; Jakupec MA; Galanski MS; Keppler BK
    Dalton Trans; 2012 Dec; 41(47):14404-14415. PubMed ID: 22886297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity.
    Xu Z; Wang Z; Yiu SM; Zhu G
    Dalton Trans; 2015 Dec; 44(46):19918-26. PubMed ID: 26514681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diamminetetrakis(carboxylato)platinum(IV) complexes--synthesis, characterization, and cytotoxicity.
    Hoffmeister BR; Adib-Razavi MS; Jakupec MA; Galanski M; Keppler BK
    Chem Biodivers; 2012 Sep; 9(9):1840-8. PubMed ID: 22976974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative measurement of the reduction of platinum(IV) complexes using X-ray absorption near-edge spectroscopy (XANES).
    Hall MD; Daly HL; Zhang JZ; Zhang M; Alderden RA; Pursche D; Foran GJ; Hambley TW
    Metallomics; 2012 Jun; 4(6):568-75. PubMed ID: 22569908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fresh platinum complexes with promising antitumor activity.
    Wang X
    Anticancer Agents Med Chem; 2010 Jun; 10(5):396-411. PubMed ID: 20545618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. East-west fusion-necrosis and apoptosis acting in concert by demethylcantharidin-integrated platinum complexes.
    Pang SK; So WK; Ho YP; Au-Yeung CF
    Anticancer Agents Med Chem; 2014 Jun; 14(5):756-61. PubMed ID: 24476313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel cis- and trans-configured bis(oxime)platinum(II) complexes: synthesis, characterization, and cytotoxic activity.
    Scaffidi-Domianello YY; Meelich K; Jakupec MA; Arion VB; Kukushkin VY; Galanski MS; Keppler BK
    Inorg Chem; 2010 Jun; 49(12):5669-78. PubMed ID: 20459062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells.
    Alvarez-Valdés A; Pérez JM; López-Solera I; Lannegrand R; Continente JM; Amo-Ochoa P; Camazón MJ; Solans X; Font-Bardía M; Navarro-Ranninger C
    J Med Chem; 2002 Apr; 45(9):1835-44. PubMed ID: 11960495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxicity of cis-platinum(II) conjugate models. The effect of chelating arms and leaving groups on cytotoxicity: a quantitative structure-activity relationship approach.
    Monti E; Gariboldi M; Maiocchi A; Marengo E; Cassino C; Gabano E; Osella D
    J Med Chem; 2005 Feb; 48(3):857-66. PubMed ID: 15689170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum(IV) Complexes of
    Papadia P; Micoli K; Barbanente A; Ditaranto N; Hoeschele JD; Natile G; Marzano C; Gandin V; Margiotta N
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.
    Kelland LR; Barnard CF; Mellish KJ; Jones M; Goddard PM; Valenti M; Bryant A; Murrer BA; Harrap KR
    Cancer Res; 1994 Nov; 54(21):5618-22. PubMed ID: 7923207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the equatorial ligands for the redox behavior, mode of cellular accumulation and cytotoxicity of platinum(IV) prodrugs.
    Göschl S; Varbanov HP; Theiner S; Jakupec MA; Galanski MS; Keppler BK
    J Inorg Biochem; 2016 Jul; 160():264-74. PubMed ID: 27055943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes.
    Turánek J; Kasná A; Záluská D; Neca J; Kvardová V; Knötigová P; Horváth V; SIndlerová L; Kozubík A; Sova P; Kroutil A; Zák F; Mistr A
    Anticancer Drugs; 2004 Jun; 15(5):537-43. PubMed ID: 15166629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multifunctional Pt(iv) prodrug candidates featuring the carboplatin core and deferoxamine.
    Harringer S; Hejl M; Enyedy ÉA; Jakupec MA; Galanski MS; Keppler BK; Dyson PJ; Varbanov HP
    Dalton Trans; 2021 Jun; 50(23):8167-8178. PubMed ID: 34031671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel oximato-bridged platinum(II) di- and trimer(s): synthetic, structural, and in vitro anticancer activity studies.
    Scaffidi-Domianello YY; Legin AA; Jakupec MA; Roller A; Kukushkin VY; Galanski MS; Keppler BK
    Inorg Chem; 2012 Jul; 51(13):7153-63. PubMed ID: 22691006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. trans,cis,cis-bis(benzoato)dichlorido(cyclohexane-1R,2R-diamine)platinum(IV): a prodrug candidate for the treatment of oxaliplatin-refractory colorectal cancer.
    Gandin V; Marzano C; Pelosi G; Ravera M; Gabano E; Osella D
    ChemMedChem; 2014 Jun; 9(6):1299-305. PubMed ID: 24715720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.